Archived 5 years ago from Global ResearchIn Rush for Regulatory Approval of COVID Vaccines, Do We Need More Data?
After rollout under emergency authorisation, manufacturers of COVID vaccines now have their sights on regulatory approval — but should we rush approval based on only six months’ worth of data from unblinded trials? In April 2021, Pfizer and Moderna announced efficacy results at the six-month mark …
Read More